OPPM
MDGL icon

Opus Point Partners Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Opus Point Partners Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,570
Closed -$374K – 61
2019
Q2 		$374K Hold
3,570
– – 0.55% 44
2019
Q1 		$447K Buy
+3,570
New +$444K 0.61% 40

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Opus Point Partners Management's MDGL Position: Q3 2019 in Review

Opus Point Partners Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2019, closing a stake of 3,570 shares — an estimated $374K sold.

Opus Point Partners Management first reported a position in MDGL in Q1 2019 and held it in 2 quarters. The position peaked at $447K in Q1 2019. 111 funds tracked by Wall St. Rank hold MDGL as of Q3 2019.

  • Opus Point Partners Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 3,570 Madrigal Pharmaceuticals shares in Q3 2019, an estimated $374K.
  • Opus Point Partners Management first reported a position in Madrigal Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Opus Point Partners Management's Madrigal Pharmaceuticals position peaked at $447K in Q1 2019.
  • 111 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.